Virus News and Research

Latest Virus News and Research

Antigenics announces positive results of AG-707 genital herpes vaccine

Antigenics announced positive results with AG-707, an investigational therapeutic vaccine being developed to treat herpes simplex virus-2,the virus that causes genital herpes, in infected patients. Developed by Antigenics, the vaccine triggers a cellular immune response, stimulating both CD4+ and CD8+ T cells.

28 Jul 2010

InterMune second-quarter total revenue decreases to $5.9 million

InterMune, Inc. today announced results from operations for the second quarter and six months ended June 30, 2010. InterMune also highlighted its recent clinical development and business activities, and provided forward-looking financial guidance for 2010.

28 Jul 2010

Singapore hepatitis C therapeutics market revenue to increase to $4.5 billion by 2017

The Singaporean government's emphasis on raising awareness on the benefit of frequent health check-ups have significantly raised the number of Hepatitis C Virus (HCV) diagnosed cases in the country, expanding the patient pool. Therapeutics companies have a challenging task ahead for improving treatment for this market as current treatment requires high dosage frequency, but potentially has serious side effects.

27 Jul 2010

Global Fund director calls on emerging countries to invest more in programs to reduce HIV/AIDS, TB and malaria at AIDS 2010

On the final day of the International AIDS Conference-AIDS 2010 Friday, Michel Kazatchkine, executive director of the Global Fund to Fight AIDS, Tuberculosis and Malaria called upon "China, India and other fast-growing economies" to chip in to help close the funding gap in efforts to battle HIV/AIDS, Agence France-Presse reports. "Until now, these countries have been recipients of AIDS funds, not donors," the news service writes.

27 Jul 2010

Albert Einstein College of Medicine receives research grant to help people with MDR-TB

For the third time in four months, the National Institute of Allergy and Infectious Diseases of the National Institutes of Health has awarded Albert Einstein College of Medicine of Yeshiva University a research grant aimed at helping people infected with multidrug-resistant tuberculosis. Taken together, all three NIH grants total $8.57 million.

27 Jul 2010

Abbot's innovative solutions to be highlighted at AACC

A first-of-its-kind test that detects HIV infection earlier than ever before in the United States; a molecular assay for identification of two common sexually transmitted diseases; and an enhanced integrated analyzer offering significant workflow improvements; are among the many new advances Abbott will highlight at this year's American Association for Clinical Chemistry Lab Expo which starts today in Anaheim.

27 Jul 2010

GenVec creates novel vectors for vaccine development

GenVec, Inc. announced that research regarding GenVec's efforts to create novel vectors for vaccines is appearing in Vol. 28, issue 35, pages 5691-5702 of Vaccine. The article, "Potent immune responses and in vitro pro-inflammatory cytokine suppression by a novel adenovirus vector based on rare human serotype 28," describes GenVec's efforts to identify and utilize novel adenovirus serotypes as vectors in vaccine development.

27 Jul 2010

Idenix second-quarter total revenues decrease to $1.3 million

Idenix Pharmaceuticals, Inc., a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today reported unaudited financial results for the second quarter and six months ended June 30, 2010. At June 30, 2010, Idenix's cash and cash equivalents totaled $51.0 million.

27 Jul 2010

Quidel recommences shipments of QuickVue+ lateral flow diagnostic test for infectious mononucleosis

Quidel Corporation, a leading provider of rapid diagnostic testing solutions, announced today that it has begun taking orders for its QuickVue®+ lateral flow diagnostic test for infectious mononucleosis. Due to strong customer demand, the Company has restarted manufacturing its previous mononucleosis product with shipments to customers expected during the first week of August.

27 Jul 2010

Scientists discover mechanism of herpes virus cell entry machinery

The mechanism by which a herpes virus invades cells has remained a mystery to scientists, but now research from Tufts University and the University of Pennsylvania reveals the unusual structure of a key member of the protein complex that allows a herpes virus to invade cells.The new map details an essential piece of the herpes virus "cell-entry machinery," providing scientists with a new target for antiviral drugs.

27 Jul 2010

Can-Fite's CF102 decreases HCV viral load in liver cancer patients

Can-Fite BioPharma Ltd, a biotechnology company traded on the Tel Aviv Stock Exchange reported today that a significant decrease in HCV viral load was detected in 3 patients with liver cancer who are treated daily orally with CF102. The company is studying CF102 as a treatment for liver cancer (hepatocellular carcinoma, or HCC). The results announced today relate to data which came out of a Phase 1/2 clinical trial of CF102 in the treatment of patients with advanced HCC.

26 Jul 2010

Vical's prophylactic Vaxfectin-formulated pDNA vaccine effective against HSV-2 in animal model

Vical Incorporated today announced that its prophylactic Vaxfectin®-formulated plasmid DNA (pDNA) vaccine against herpes simplex virus type 2 (HSV-2) protected mice against lethal challenge, provided sterilizing immunity and inhibited viral counts at both the primary and latent infection sites. The Vaxfectin® adjuvant substantially improved vaccine effectiveness. A related vaccine significantly reduced the recurrence of HSV-2 lesions in a therapeutic model using guinea pigs with latent infection.

26 Jul 2010

North Shore-LIJ Health System seeks oropharynx patients for phase I clinical trial

The North Shore-LIJ Health System Department of Radiation Medicine announced today it is seeking patients with cancer of the oropharynx (back of the mouth) to participate in a Phase I clinical trial.Subjects must be newly diagnosed and not have undergone any previous treatment. Further, their cancer must be unassociated with the human papilloma virus (HPV-negative), or, if it is HPV-positive, they must be current or former pack-a-day smokers for at least 10 years.

26 Jul 2010

Toolkits to facilitate implementation of new WHO guidelines for reducing HIV infections issued

At the XVIII International AIDS Conference, the Elizabeth Glaser Pediatric AIDS Foundation has issued the first of a series of three linked toolkits to facilitate the adaptation and implementation of the revised World Health Organization recommendations for four technical areas: antiretroviral drugs for treating pregnant women and preventing HIV infection in infants, infant feeding in the context of HIV, and antiretroviral treatment for children, adolescents, and adults.

26 Jul 2010

AIDS 2010: Obama, Clinton vow U.S. support to global fight against HIV/AIDS

During the closing ceremonies of the International AIDS Conference-AIDS 2010, President Barack Obama "on Friday pledged to redouble efforts to fight HIV and AIDS through his Global Health Initiative, despite dealing with economic hard times in the wake of a global recession," Reuters reports. According to the news service, "Obama and his Secretary of State Hillary Clinton said their focus was on a broad, sustainable and effective approach to the global epidemic" (Kelland, 7/23).

26 Jul 2010

Einstein scientists awarded $4.1M to test microbicide Carraguard against HPV

The National Cancer Institute has awarded Albert Einstein College of Medicine of Yeshiva University $4.1 million to test the microbicide Carraguard- against the human papillomavirus, which causes cervical cancer. The research will evaluate the efficacy of Carraguard- - a clear gel made from the seaweed derivative carrageenan - in preventing new HPV infections in women.

26 Jul 2010

Organizations highlight plight of HIV-positive Haitians, call for donors to support 'whole of society' health system strengthening

Organizations attending the International AIDS Conference-AIDS 2010 highlighted the plight of HIV-positive earthquake survivors in Haiti who are "still waiting for aid promised to them before" the quake as rebuilding efforts slowly move along, Agence France-Presse reports.

23 Jul 2010

ASH to honor six scientists for treatment of hematologic diseases

The American Society of Hematology (ASH), the world's largest professional society of blood specialists, will honor six scientists who have made significant contributions to the understanding and treatment of hematologic diseases. These awards will be presented at the 52nd ASH Annual Meeting taking place December 4-7 in Orlando.

23 Jul 2010

National Jewish Health receives $31M NIH contract to study skin infections associated with atopic dermatitis

The National Institute of Allergy and Infections Disease has awarded a five-year $31 million contract to National Jewish Health, which is leading a consortium of academic medical centers seeking to better understand skin infections associated with atopic dermatitis. The researchers will focus on antibiotic-resistant staphylococcus aureus (MRSA) infections and widespread viral infections of the skin, both of which are more prevalent among atopic dermatitis patients.

23 Jul 2010

Reusing syringes in anesthesia leads to viral transmission: Study

Hepatitis B virus and hepatitis C virus can be transmitted during intravenous administration of anesthesia, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association Institute. In this study, doctors found that anesthesia contamination - not endoscopy contamination - was the cause of infection.

23 Jul 2010

Virus News and Research

Latest Virus News and Research

Antigenics announces positive results of AG-707 genital herpes vaccine

InterMune second-quarter total revenue decreases to $5.9 million

Singapore hepatitis C therapeutics market revenue to increase to $4.5 billion by 2017

Global Fund director calls on emerging countries to invest more in programs to reduce HIV/AIDS, TB and malaria at AIDS 2010

Albert Einstein College of Medicine receives research grant to help people with MDR-TB

Abbot's innovative solutions to be highlighted at AACC

GenVec creates novel vectors for vaccine development

Idenix second-quarter total revenues decrease to $1.3 million

Quidel recommences shipments of QuickVue+ lateral flow diagnostic test for infectious mononucleosis

Scientists discover mechanism of herpes virus cell entry machinery

Can-Fite's CF102 decreases HCV viral load in liver cancer patients

Vical's prophylactic Vaxfectin-formulated pDNA vaccine effective against HSV-2 in animal model

North Shore-LIJ Health System seeks oropharynx patients for phase I clinical trial

Toolkits to facilitate implementation of new WHO guidelines for reducing HIV infections issued

AIDS 2010: Obama, Clinton vow U.S. support to global fight against HIV/AIDS

Einstein scientists awarded $4.1M to test microbicide Carraguard against HPV

Organizations highlight plight of HIV-positive Haitians, call for donors to support 'whole of society' health system strengthening

ASH to honor six scientists for treatment of hematologic diseases

National Jewish Health receives $31M NIH contract to study skin infections associated with atopic dermatitis

Reusing syringes in anesthesia leads to viral transmission: Study

A new way of characterising biomolecules eBook

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Virus News and Research

Latest Virus News and Research

A new way of characterising biomolecules eBook

Transforming Cardiovascular Care: Insights from Mina Makar at AstraZeneca

Clue's CEO Rhiannon White on the Future of Femtech and PCOS

Freezing Point Osmometry in Life Science Applications

Newsletters you may be interested in